Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
47.55
+0.14 (0.30%)
Mar 3, 2025, 4:00 PM EST - Market closed
Exact Sciences Employees
Exact Sciences had 7,000 employees as of December 31, 2024. The number of employees increased by 400 or 6.06% compared to the previous year.
Employees
7,000
Change (1Y)
400
Growth (1Y)
6.06%
Revenue / Employee
$394,124
Profits / Employee
-$146,980
Market Cap
8.83B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7,000 | 400 | 6.06% |
Dec 31, 2023 | 6,600 | 200 | 3.13% |
Dec 31, 2022 | 6,400 | -100 | -1.54% |
Dec 31, 2021 | 6,500 | 1,500 | 30.00% |
Dec 31, 2020 | 5,000 | 890 | 21.65% |
Dec 31, 2019 | 4,110 | 2,133 | 107.89% |
Dec 31, 2018 | 1,977 | 709 | 55.91% |
Dec 31, 2017 | 1,268 | 532 | 72.28% |
Dec 31, 2016 | 736 | 59 | 8.71% |
Dec 31, 2015 | 677 | 441 | 186.86% |
Dec 31, 2014 | 236 | 134 | 131.37% |
Dec 31, 2013 | 102 | 15 | 17.24% |
Dec 31, 2012 | 87 | 26 | 42.62% |
Dec 31, 2011 | 61 | 26 | 74.29% |
Dec 31, 2010 | 35 | 16 | 84.21% |
Dec 31, 2009 | 19 | 15 | 375.00% |
Dec 31, 2008 | 4 | -10 | -71.43% |
Dec 31, 2007 | 14 | -8 | -36.36% |
Dec 31, 2006 | 22 | -27 | -55.10% |
Dec 31, 2005 | 49 | -22 | -30.99% |
Dec 31, 2004 | 71 | -11 | -13.41% |
Dec 31, 2003 | 82 | 7 | 9.33% |
Dec 31, 2002 | 75 | 7 | 10.29% |
Dec 31, 2001 | 68 | 24 | 54.55% |
Dec 31, 2000 | 44 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
EXAS News
- 7 days ago - Exact Sciences to Participate in March Investor Conferences - Business Wire
- 7 days ago - Exact Sciences: A Strong Q4 Reveals Signs Of A Potential Inflection Point - Seeking Alpha
- 11 days ago - Exact Sciences Corporation (EXAS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Exact Sciences Announces Fourth Quarter 2024 Results - Business Wire
- 13 days ago - U.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy's Petition Challenging Validity of a Second Patent Asserted by Exact Sciences - Business Wire
- 26 days ago - Flatiron Health and Exact Sciences Partner to Advance Clinical Evidence Generation for Molecular Residual Disease Testing - Business Wire
- 4 weeks ago - Exact Sciences Schedules Fourth Quarter 2024 Earnings Call - Business Wire
- 5 weeks ago - Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium - Business Wire